FDA selects Emyria for in-person speaking position at landmark psychedelic medicines hearing
Emyria Limited (ASX: EMD) has been selected by the U.S. Food and Drug Administration (FDA) to deliver in-person remarks at the public hearing “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” scheduled for 14 September 2026 at the FDA’s White Oak Campus in Silver Spring, Maryland. The company secured one of a limited number of in-person speaking positions at the hearing, placing it directly inside a U.S. federal policy discussion on the future delivery of psychedelic medicines.
| Detail | Information |
|---|---|
| Hearing name | Considerations for Potential Future Therapeutic Use of Psychedelic Drugs |
| Date | 14 September 2026, 12:30–4:30 pm ET |
| Location | FDA White Oak Campus, Silver Spring, Maryland |
| Emyria’s position | One of a limited number of in-person speaking roles |
The FDA convened the hearing to gather perspectives on the potential future therapeutic use of psychedelic drug products in supervised and supportive settings, including practical considerations relevant to safe, effective, and scalable treatment delivery. The audience comprises regulatory authorities, drug sponsors, providers, and other relevant stakeholders.
When big ASX news breaks, our subscribers know first
What Emyria will bring to the FDA table
The four principal discussion areas the FDA has identified for the hearing align directly with Emyria’s existing Australian clinical operations. The company is entering the room with practical, real-world answers rather than theoretical frameworks.
The FDA’s four areas for discussion are:
- Provider training and credentialing
- Promotion of patient safety
- Considerations for access
- Best practices for data collection and standardisation
Emyria’s Australian clinical operations already span each of these areas. The capabilities the company has built through Australia’s regulated psychedelic-assisted therapy framework include:
Emyria’s PTSD remission outcomes show two-thirds of treatment-resistant patients maintaining clinical remission more than 12 months post-treatment, with a median 28-day time to remission, the kind of real-world evidence that gives the company’s FDA submission its empirical grounding.
- Psychiatrist-led clinical governance and authorised prescribing
- Therapist recruitment, training and credentialing
- Patient screening, preparation, dosing and follow-up
- Specialist treatment facilities and clinical infrastructure
- Systematic collection of clinical outcomes and real-world evidence
Operating under Australia’s regulated framework since 2023
Australia permits authorised psychiatrists to prescribe MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD) within regulated clinical settings. Emyria has been operating within this framework since 2023, accumulating direct clinical, workforce, infrastructure, and data experience across the treatment pathway. This real-world operating history is the foundation of the company’s contribution to the FDA hearing.
Why the U.S. market matters for Emyria investors
The United States is the world’s largest healthcare market by expenditure, with healthcare spend reaching approximately US$5.3 trillion in 2024. The scale of that opportunity gives the FDA appearance a significance that extends well beyond symbolic recognition.
The selection places Emyria’s clinical capabilities and real-world evidence platform directly in front of U.S. regulators, industry participants, and potential partners as the company evaluates U.S. opportunities. The company is actively assessing how to deploy its Australian experience through a range of pathways, including:
The Empax Global Partnership Program, which offers Emyria’s clinical delivery infrastructure to international drug sponsors under a capital-light model, broadens the commercial pathways that a U.S. regulatory presence could accelerate beyond direct patient treatment alone.
- Clinical partnerships
- Treatment-delivery collaborations
- Research programs
- Real-world evidence initiatives
Greg Hutchinson, Executive Chair
“Being selected to address the FDA hearing gives Emyria a rare opportunity to bring real-world experience from Australia directly in front of U.S. regulators. We have operated under Australia’s regulated framework since 2023, giving us practical experience across the same areas the FDA is now examining — provider training, patient safety, access and real-world data.
“The United States is the world’s largest healthcare market, and this hearing puts Emyria directly into an important federal discussion about how psychedelic medicines may ultimately be delivered. It provides a unique platform to demonstrate what we have already built in Australia as we pursue opportunities to apply that experience in the United States.”
Understanding psychedelic-assisted therapy and the regulatory moment
Psychedelic-assisted therapy refers to the use of controlled substances such as MDMA or psilocybin, administered in a supervised clinical setting and combined with structured psychological support. MDMA is being studied for PTSD, while psilocybin is being examined for TRD — conditions that often prove resistant to conventional treatments.
Regulators globally are now grappling with a shared challenge: how to structure the delivery of these therapies at scale in a way that is safe, effective, and accessible. The FDA hearing represents a meaningful policy moment, as U.S. regulators seek input on the practical frameworks that could govern future therapeutic use.
Emyria’s position in this moment is notable. The company has been delivering these therapies within a regulated environment in Australia while the U.S. is still in the process of designing its framework. That operational head start, across training, infrastructure, governance, and data collection, is what the company is bringing to Silver Spring on 14 September 2026.
What comes next for Emyria
The hearing takes place on 14 September 2026, just days from this announcement. Emyria is actively evaluating U.S. opportunities, and the FDA appearance represents a platform rather than an endpoint in that process. Investors should note that the source uses “evaluates opportunities” language, and no specific expansion plans or timelines have been announced.
Near-term investor watch points include:
- Emyria’s in-person remarks at the 14 September 2026 FDA hearing
- FDA outcomes and any signals on the regulatory framework for psychedelic medicines delivery
- Company updates on U.S. market evaluation progress
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market on announcements just like this one. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.